Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (Symbol: CDXS) is a pioneering leader in protein engineering, pushing the boundaries of biotechnology through its innovative approaches. Established in 2002, Codexis specializes in the rapid development and production of highly optimized proteins using its proprietary CodeEvolver® technology platform. This platform leverages the power of artificial intelligence and advanced high-throughput screening systems to efficiently introduce function-driven mutations, creating proteins meticulously tailored to meet specific performance requirements.
Codexis offers a broad spectrum of enzyme optimization services and biocatalyst products. These include biocatalysts and enzymes, which play crucial roles in various industries, including pharmaceuticals, food, and biofuels. The company's enzyme solutions are designed to improve the efficiency, cost-effectiveness, and environmental sustainability of production processes.
A significant portion of Codexis’ revenue is derived from product sales, while licensing its technology platform to pharmaceutical companies also contributes to its financial health. These partnerships enable pharmaceutical giants to harness Codexis’ technology in-house, facilitating the engineering of custom enzymes for their specific needs.
Codexis has a global revenue footprint, with contributions from the United States, Ireland, Switzerland, China, and other international markets. The company's innovative efforts have led to several strategic partnerships and collaborations, further cementing its position in the biotechnology sector.
Recent achievements include a strategic collaboration geared towards enhancing RNA therapeutic development, aimed at providing GMP-grade Codexis enzymes. Another notable development is the collaboration with TnX transposase, focusing on enhancing genomic applications.
Codexis continues to advance in the field of biotherapeutics, retaining economic interest while minimizing development and commercialization costs. The company remains committed to optimizing yield, purity, and quality in its offerings, ensuring that customers receive superior siRNA materials for preclinical testing.
For more information, Codexis frequently participates in industry conferences, presenting breakthrough research and advancements. Stay updated with the latest developments and announcements by following Codexis on various platforms.
Codexis (Nasdaq: CDXS) announced an extension of its agreement with Merck to license and supply a proprietary enzyme used in the manufacturing of sitagliptin, the API in Merck’s JANUVIA® and JANUMET®. This partnership, which has lasted over a decade, will now extend through December 31, 2026, with a potential 5-year renewal. The enzyme enhances manufacturing efficiency, reducing costs and waste. Codexis and Merck previously won the EPA's Presidential Green Chemistry Challenge Award for their innovative manufacturing method.
Codexis (Nasdaq:CDXS), an enzyme engineering leader, announced its participation in two virtual investment conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, featuring an on-demand corporate presentation. Following that, the Cantor Virtual Global Healthcare Conference is scheduled for September 28, 2021, with a fireside chat at 10:40 a.m. ET. Webcasts of both events will be available on the Company's Investor Relations website for 90 days post-event, highlighting Codexis' advancements in synthetic biology and enzyme technology.
Orders Support Company’s Recently Increased 2021 Guidance
Codexis (Nasdaq: CDXS) announced new purchase orders totaling approximately $15 million for 2021, related to a proprietary enzyme for a global pharmaceutical client. These orders align with the forecast provided on August 5, projecting total revenues between $98 - $103 million and product revenues of $59 - $63 million. This marks an increase in guidance, with strong market demand anticipated. CEO John Nicols praised the team's commitment, indicating it will be the largest annual product sale in the company's history.
Codexis (CDXS) reported a remarkable second quarter, achieving a record product revenue of $14.7 million, a surge of 227% year-over-year. The product gross margin also reached a high of 71%, attributed to a favorable sales mix. The company has raised its FY 2021 revenue guidance to $98 - $103 million and product revenue guidance to $59 - $63 million. Key highlights include significant orders from global pharmaceutical companies and expansion of partnerships, notably with Takeda, reflecting strong demand in their enzyme products and biotherapeutics.
Codexis (Nasdaq: CDXS) and Kalsec have expanded their research collaboration and entered an exclusive supply agreement for a novel enzyme aimed at producing Kalsec's latest natural hop acid. Developed using Codexis' CodeEvolver® platform, this enzyme enhances functionality, stability, and efficiency, promising commercial production by early 2022. Kalsec's CEO emphasized the importance of this innovation for meeting market demand for high-performing hop products, while Codexis' CEO highlighted the sustainable benefits of their enzyme technology for food and beverage manufacturing.
Codexis (CDXS) and Kalsec have expanded their research collaboration, entering into an exclusive supply agreement for a new enzyme aimed at producing Kalsec's latest natural hop acid. This enzyme, developed using Codexis’ CodeEvolver technology, enhances functionality, stability, and efficiency, enabling commercial-scale production by early 2022. The partnership aims to create innovative, sustainable bioprocesses, contributing to product differentiation in the competitive food and beverage market. Both companies emphasize sustainability and the potential for reduced manufacturing costs.
Codexis, Inc. (Nasdaq:CDXS) will announce its Q2 2021 financial results on August 5, 2021. A conference call will follow at 4:30 p.m. ET for discussion and updates. The company specializes in enzyme engineering and aims to enhance sustainable manufacturing across various sectors, including pharmaceuticals and food. Their proprietary CodeEvolver® platform drives innovation in biotherapeutics and diagnostics while improving resource efficiency. Investors can access the live call via the Codexis Investor Relations website.
Codexis, Inc. (CDXS) announced the successful completion of its CodeEvolver® platform technology transfer to Novartis Pharma AG. This collaboration, initiated in May 2019, allows Novartis to utilize CodeEvolver® for developing high-performance enzymes in pharmaceutical manufacturing. The new enzymes promise reduced capital requirements, higher yields, and lower energy usage compared to conventional chemistry methods. Codexis has now achieved three similar collaborations, with this being the first conducted virtually due to the pandemic's challenges.
Codexis (Nasdaq: CDXS) announced a milestone payment from GlaxoSmithKline related to its CodeEvolver® protein engineering platform. This payment, recognized as revenue in Q2 2021, signifies progress in the licensing agreement for an enzyme aimed at enhancing drug manufacturing. Codexis continues to strengthen its partnership with GSK, emphasizing the potential for significant long-term revenue from CodeEvolver. The company manages relationships with three leading pharmaceutical firms, indicating a promising outlook for enzyme commercialization and synthetic biology applications.
Codexis (Nasdaq: CDXS) increases its 2021 revenue guidance to $89-$93 million, up from $82-$85 million, after securing a $13.9 million purchase order for its high-performance enzyme product from a global pharmaceutical company. Product revenue guidance is also raised to $45-$48 million from $36-$39 million, with gross margin expectations now at 60%-64%, up from 54%-58%. This growth reflects Codexis' capacity to enhance revenue and margin through its innovative enzyme engineering platform.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
What does Codexis, Inc. specialize in?
How does Codexis generate revenue?
What industries benefit from Codexis’ products and services?
What is the CodeEvolver® technology platform?
Where does Codexis derive its revenue from geographically?
What recent collaborations has Codexis entered into?
What is the significance of Codexis’ strategic collaborations?
What recent achievements has Codexis made in biotherapeutics?
How does Codexis ensure the quality of its products?
How can I stay updated with Codexis’ latest news and developments?
